Volume 123, Issue 1 , Pages 43-52.e7, January 2009
Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein
Background
About 70% of children with milk allergy tolerate extensively heated milk (HM) products and outgrow their allergy earlier than those who react to HM.
Objective
To test the hypothesis that HM-tolerant children have a higher precursor frequency of adaptive allergen-specific regulatory T (Treg) cells.
Methods
Allergic, HM-tolerant, outgrown, or control subjects were defined by oral food challenge. PBMCs were cultured with purified caseins and controls for 7 days, and proliferating CD25+CD27+ Treg cells were identified by flow cytometry. Proliferating cells were also characterized for their expression of FoxP3, CTLA 4, CD45RO, and CD127. Allergen-specific Treg cell origin and function were assessed by depletion of CD25hi cells before culture.
Results
There was a higher percentage (median [25th% to 75th%], 16.85% [7.1-31.7]) of proliferating allergen-specific CD25+CD27+ T cells from cultures of HM-tolerant subjects (n = 18) than subjects with allergy (n = 8; 4.91% [2.6-7.5]; P < .01). Control subjects with no history of milk allergy (n = 7) also had low percentages of these cells (2.9% [2.4-6.0]), whereas outgrown subjects (n = 7) had intermediate percentages (9.0% [2.7-16.4]). There were no significant differences between the patient groups in the frequency of polyclonal Treg cells or allergen-specific effector T cells. Allergen-specific Treg cells were found to be FoxP3+CD25hiCD27+, cytotoxic T lymphocyte–associated antigen 4+, CD45RO+CD127− and were derived from circulating CD25hi T cells. Depletion of the CD25hi cells before in vitro culture significantly enhanced allergen-specific effector T-cell expansion.
Conclusion
A higher frequency of milk allergen-specific Treg cells correlates with a phenotype of mild clinical disease and favorable prognosis.
Key words: Treg, FoxP3, CTLA-4, immune tolerance, oral tolerance, food allergy, milk allergy
Abbreviations used: CTLA, Cytotoxic T lymphocyte–associated antigen, HM, Heated milk, NHM, Nonheated milk, Treg, Regulatory T
Supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases U19 AI-44236, NCRR M01-RR00071. W.G.S. receives additional support from National Institute of Allergy and Infectious Diseases K08 AI067722-01A2, the Extramural Pediatric National Institutes of Health-Loan Repayment Program, and the Food Allergy Initiative.
Disclosure of potential conflict of interest: W. G. Shreffler has received research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases and the Food Allergy and Anaphylaxis Network. A. Nowak-Wegrzyn has received research support from the National Institutes of Health and has served as a member of the New York Allergy and Asthma Society. H. A. Sampson owns stock in Allertein Therapeutics, has received research support from the Food Allergy Initiative and the National Institutes of Health/National Institute of Allergy and Infectious Diseases, and has served as a member of the Food Allergy Initiative and the American Academy of Allergy, Asthma & Immunology. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(08)01868-X
doi:10.1016/j.jaci.2008.09.051
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 123, Issue 1 , Pages 43-52.e7, January 2009
